The World Health Organization has updated the current guidelines for Covid-19 drugs to advise against the use of the antiviral drug rimadesivir for the treatment of hospitalized patients, no matter how severe their illness.
According to an update published in BMJ’s medical journal on Thursday, current evidence does not indicate that rimadasivir affects covid-19 death or the need for mechanical ventilation, among other important consequences.
WHO’s new update comes a month after Gilead Sciences, the company that makes remodeciver, reports that U.S. Remadesivir has been approved by the Food and Drug Administration for the treatment of coronavirus infections. The drug became the first FDA-approved coronavirus treatment.
Dr. Amesh Adalaja, a senior scholar at Johns Hopkins, said that due to the research that fills d, rimadesivir may get FDA approval but not the WHO recommendation because of the research that fills WH. Health Safety Center, which was not involved in WHO guidance.
“We’ve seen people see that the benefit of rimadesivir is the most marginal – and the only benefit we’ve been getting is that people probably get it more quickly. Reflecting in the guidance, just a further evaluation of the data out there and now, ”Adalaja told CNN on Thursday.
“The fact that it was an antiviral that showed little benefit in some trials – but not in all tests – was enough to force people to use it because we don’t have the tools, but I think it will be filled soon. Adalaja added that the indication for the drugs may change over time.
Some references: The WHO called an international panel of 24 experts and four survivors of the Covid-19 to review the data and make recommendations. The recommendation against Remedesivir was based on data from four randomized trials involving 7,333 hospitalized patients in Covid-19.
“The panel concludes that most patients will not choose intravenous treatment with remedicivir based on less conclusive evidence,” researchers from various organizations around the world wrote in the WHO’s updated guideline.
.
